At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms. That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.
http://investor.agenusbio.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.3 seconds
PAGES IN
THIS WEBSITE
7
SSL
EXTERNAL LINKS
73
SITE IP
204.8.173.159
LOAD TIME
0.277 sec
SCORE
6.2
Agenus Bio Investor Center | | investor.agenusbio.com Reviews
https://investor.agenusbio.com
At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms. That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.
investor.agenusbio.com
Analyst Coverage – Agenus
http://investor.agenusbio.com/analyst-coverage
Below is a list of individual analysts that we are aware of that currently follow Agenus. Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent Agenus or its management team. Agenus is under no obligation to update this list, thus it may not be complete or up to date. Michael King, Jr. HC Wainwright and Co. WILLIAM BLAIR and Co. Terms and Conditions of Use.
Presentations and Webcasts | Agenus Bio Investor Center
http://investor.agenusbio.com/presentation-webcasts
Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. There are no scheduled events at this time. Please check back later. Agenus Second Quarter 2016 Financial Results. Annual Meeting of Stockholders. Business Wire InvestorHQ℠.
First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review | Agenus Bio Investor Center
http://investor.agenusbio.com/press-release/first-vaccine-candidate-malaria-accepted-eu-regulatory-review
Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review. GSK’s RTS,S is the world’s first malaria vaccine candidate to undergo regulatory review. Is a component of RTS,S and in 16 additional vaccine candidates undergoing patient studies. Submission triggered regulatory milestone payment; Agenus entitled to royalties on product sales. Thursday, July 24, 2014 6:01 am EDT. RTS,S has th...
Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant | Agenus Bio Investor Center
http://investor.agenusbio.com/press-release/positive-outcome-phase-3-study-gsk-shingles-vaccine-containing-agenus-adjuvant
Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant. GSK’s ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older. Agenus is entitled to receive royalties on potential commercial sales of HZ/su. Thursday, December 18, 2014 7:19 am EST. We are thrilled with the results of this important study". We are thrilled with the...
Press Releases - all | Agenus Bio Investor Center
http://investor.agenusbio.com/press-releases/all/all/all
Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. Agenus Reports Second Quarter 2016 Financial Results and Operational Progress. 7/28/16 8:50 am EDT. LEXINGTON, Mass.- ( BUSINESS WIRE. Agenus to Report Second Quarter 2016 Financial Results on July 28, 2016; Conference Call to Follow. 7/21/16 8:50 am EDT. LEXINGTON, Mass.- ( BUSINESS WIRE. Agenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development. Agenus In...
TOTAL PAGES IN THIS WEBSITE
7
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/pipeline
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/careers
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/collaborations/in-licensing
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/collaborations
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
Careers - Agenus
https://careers-agenusbio.icims.com/about
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
Careers - Agenus
https://careers-agenusbio.icims.com/jobs/intro
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/about
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
globalcareers-agenusbio.icims.com
Careers - Agenus
https://globalcareers-agenusbio.icims.com/collaborations/out-licensing
Working Together to Cure Cancer. Terms and Conditions of Use. Terms and Conditions of Use.
TOTAL LINKS TO THIS WEBSITE
73
Aeolus Pharmaceuticals - Investor Relations
About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Jun 8, 2017. May 15, 2017. View all releases ».
Reports, Filings & Statements - Investor Info | Aetna
Click Menu to close. Click to open Menu. Reports, Filings and Statements. Reports, Filings and Statements. View, print or download financial reports including earnings releases, financial supplements, guidance summaries, Form 10Qs and 10Ks. Snapshot of Aetna’s current financial metrics, ratios and trading statistics. Search Aetna’s SEC filings library and download the documents, including Section 16 filings, in pdf or html format. Reports, Filings, and Statements. You are now leaving the Aetna website.
AFFINIA - SEC Filings
SEC Filing Keyword Search. View SEC Groupings descriptions. View Section 16 Filings (3,4,5). Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Quarterly report which provides a continuing view of a company's financial position. Report of unscheduled material events or corporate event. Annual report which provides a comprehensive overview of the company for the past year.
Affymetrix - About Affymetrix - Investors - Investors
Powered by Affymetrix Partners. Aug 07 15 4:00 pm ET. The stock price performance shown on the quote above is not necessarily indicative of future price performance. Q2 2015 Affymetrix Earnings Conference Call. 160;at 5:00 pm ET. Q2 2015 Affymetrix Earnings Conference Call. Wednesday, July 29, 2015 . 5:00 pm ET . Click here for webcast. Click here to add this event to your calendar. VP Investor Relations and Treasury. Affymetrix Reports Second Quarter 2015 Operating Results. SANTA CLARA, Calif.- (BU...
Alliance Fiber Optic Products, Inc. - Investor Relations
Skip to Main Content. Annual Report and Proxy. Proxy Statement - Annual Meeting. At Alliance Fiber Optic Products, Inc. (NASDAQ: AFOP). View all ». Jul 22, 2015. AFOP Reports Record Quarterly Sales in Q2 2015; Guidance for Year-Over-Year Increases of 33% in Q3 2015. Jul 6, 2015. AFOP Announces the Second Quarter Preliminary Results With Record Revenues, and the Second Quarter Conference Call Invitation.
Agenus Bio Investor Center |
Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. July 24, 2015. GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa. July 23, 2015. Agenus Reports Second Quarter 2015 Financial Results. July 20, 2015. Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1. July 16, 2015. Agenus to Report Second Quarter 2015 Financial...
Agilent | Investor Overview
Q3 2015 Agilent Technologies Inc. Earnings Conference Call. August 17, 2015. 160;at 1:30 pm PT. AGILENT TECHNOLOGIES COMPLETES SPIN-OFF OF KEYSIGHT TECHNOLOGIES. On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business, now called Keysight Technologies. All of the outstanding shares in Keysight were distributed to Agilent shareholders on November 1, 2014. Keysight Investor Relations Website. August 17, 2015.
Overview- Agios
Annual Report and Proxy. Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. 160; 2.23. Aug 06, 2015. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. Aug 05, 2015. Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015. Jul 30, 2015.
A. H. Belo Corporation - Overview
About A. H. Belo. A H Belo Companies. Advertising with A. H. Belo. Second Quarter 2015 A. H. Belo Corporation Financial Results Conference Call - Transcript. The Dallas Morning News. Texas' leading newspaper and winner of nine Pulitzer Prizes; the. And Wanderful Media, LLC, owner of. A H Belo Corporation Announces Second Quarter 2015 Financial Results from Continuing Operations. A H Belo Corporation Announces Schedule for Second Quarter 2015 Financial Results Release and Conference Call. Â Â Past Events.
Alliance Holdings GP, L.P. -Overview
About AHGP . Investor Information . Second Quarter 2015 Alliance Resource Partners, L.P. and Alliance Holdings GP, L.P. Earnings Conference Call. 160;at 9:00 am ET. Second Quarter 2015 Alliance Resource Partners, L.P. and Alliance Holdings GP, L.P. Earnings Conference Call. Tuesday, July 28, 2015 . 9:00 am ET . Click here for webcast. Alliance Holdings GP, L.P. Reports Quarterly Financial Results and Increases Quarterly Distribution by 2.4% to $0.96 Per Unit. There are currently no events scheduled.
Home Page
Airware Labs Corporation AIRW. Regulatory Reports and Filings. Break Through Breathing Technology. Airware interview with the American Urban Radio Networks. A Harnessing Plant-Based Essential Oils To Clean Up The Oxygen Supply. AIR SLEEP/SNORE got a shout out on ABC 10 Miami as a drug-free solution to improve sleep! Study finds cognitive therapy can improve sleep without use of medication. Airware Labs Featured on Drug Topics. AirWare Featured on NBC affiliate in Sacramento. Airware Labs Featured on.
SOCIAL ENGAGEMENT